Metabolic Dysfunction-Associated Steatohepatitis (MASH) is underdiagnosed, difficult to identify, and limited in treatment options. Research studies and clinical trials for MASH are challenged in identifying and matching with qualified patients. But now, a clinical study with deep genetic and longitudinal clinical insights has the potential to be a blueprint for developing research studies across a range of disease areas.
This webinar explores how the MASH study, conducted in collaboration between Helix and Renown Health, Nevada’s largest not-for-profit integrated healthcare network, outlines protocols for an easier pathway to personalized medicine. Panelists will discuss the study’s research outcomes and how curated clinico-genomic data can help identify potential therapeutic targets and at-risk patient populations to drive precision medicine development for liver and metabolic conditions. Highlights include:
The components of the clinical study that researches an understudied disease like MASH/NASH
Collaboration between Helix and Renown Health, including an overview of the MASH study and research plan that sets a standard for joint research and clinical studies
Curation of linked clinico-genomic datasets for MASH and related groups that anchored the study and key outcomes
Implications and power of clinico-genomics for liver and metabolic research and precision medicine development